Large variation in the association between seasonal antibiotic use and resistance across multiple bacterial species and antibiotic classes

Daphne S. Sun[1], Stephen M. Kissler[1], Sanjat Kanjilal[2,3], Scott W. Olesen[1], Marc Lipsitch[1,4], Yonatan H. Grad[1,3]

1. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA
2. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
3. Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
4. Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard Chan School of Public Health, Boston, MA, USA

Correspondence: Yonatan H. Grad (ygrad@hsph.harvard.edu)

Abstract

Background. Understanding how antibiotic use drives resistance is crucial for guiding effective strategies to limit the spread of resistance, but the use-resistance relationship across pathogens and antibiotics remains unclear.

Methods. We applied sinusoidal models to evaluate the seasonal use-resistance relationship across 3 species (*Staphylococcus aureus*, *Escherichia coli*, and *Klebsiella pneumoniae*) and 5 antibiotic classes (penicillins, macrolides, quinolones, tetracyclines, and nitrofurans) in Boston, Massachusetts.

Results. Use of all 5 classes and resistance in 10 of 15 species-antibiotic combinations showed statistically significant amplitudes of seasonality ($p < 0.05$). While seasonal peaks in use varied by class, resistance in all 10 species-antibiotic combinations peaked in the winter and spring. The correlations between seasonal use and resistance thus varied widely, with resistance to all antibiotic classes being most positively correlated with use of the winter-peaking classes (penicillins and macrolides).

Conclusions. These findings challenge the simple model of antibiotic use independently selecting for resistance and suggest that stewardship strategies will not be equally effective across all species and antibiotics. Rather, seasonal selection for resistance across multiple

antibiotic classes may be dominated by use of the most highly prescribed antibiotic classes,

penicillins and macrolides.

Introduction

Antibiotic resistance is a growing threat to society, with important public health [1] and economic

consequences [2]. Antibiotic use is considered a primary driver of resistance not only in the

pathogen targeted by the antibiotic but also in host-associated bacteria subject to 'bystander

selection' [3]. As such, stewardship programs to reduce overall antibiotic prescribing have

become a popular strategy for broadly reducing the burden of resistance. However, the efficacy

of stewardship efforts has varied widely and, in some cases, shown a limited impact on reducing

rates of resistance [4,5]. These findings reflect the complexity of the antibiotic use-resistance

relationship, underscoring the need to characterize this relationship across a wide range of

bacterial species and antibiotics and identify factors that influence the strength this association.

Temporal studies have shown that an association between population-level antibiotic use and

resistance can be detected on rapid timescales, where seasonal fluctuations in use have been

accompanied by seasonal fluctuations in resistance with up to a few months lag [6–9]. To help

interpret the expected lag between seasonal use and resistance, Blanquart et al. proposed a

model for the relationship between short-term sinusoidal fluctuations in antibiotic use and

resistance [10]. This model predicts that antibiotic use determines the rate of change of

resistance, such that the derivative of the prevalence of resistance should depend on the level

of use. Thus, if antibiotic use follows a sine function over a 12-month period, then peak

resistance should lag peak use by a quarter period, or 3 months. The lag can be shortened by

including a 'stabilizing force' in the model to account for forces that counteract the effect of use

and drive fluctuations in resistance towards equilibrium.

Findings from previous seasonality studies have been largely consistent with this model.

Studies that focused on antibiotics with wintertime peaks in use (e.g. penicillins, macrolides, and

quinolones) have identified positive associations with winter/spring peaks in resistance lagged

by 0-3 months in *Streptococcus pneumoniae* [6], *Escherichia coli* [7,8], *Staphylococcus aureus*

[7], and *Neisseria gonorrhoeae* [9]. In contrast, a study from the Netherlands that analyzed

antibiotics with summer/autumn peaks in use (e.g. Nitrofurantoin, Fosfomycin, Trimethoprim)

found that resistance in *E. coli* and *Klebsiella pneumoniae* still peaked in the winter/spring and

lagged use by 3-6 months [11], inconsistent with the Blanquart et al. model. The authors of this

study attribute the longer lag time to the weaker seasonal fluctuations and lower overall rates of

antibiotic use in their study population. However, it is unclear whether resistance to other

antibiotics with winter peaks in use would exhibit similarly long lag times in this population, or

whether these findings reflect a broader phenomenon where despite different seasonal patterns

of use, resistance always peaks in the winter/spring due to other ecological factors.

We aimed to characterize the seasonal relationship between antibiotic use and resistance

across antibiotic classes with winter, summer, and biannual peaks in use [6,7,9,12] in Boston,

Massachusetts. We studied three clinically relevant species—*Staphylococcus aureus*,

Escherichia coli, and *Klebsiella pneumoniae*—which represent skin/nasal and gut colonizing

bacteria [13,14] that cause a diversity of infections types and are subject to strong bystander

selection [3]. We obtained antibiotic use data from a centralized state-wide insurance claims

database and resistance data from two major Boston-area hospitals. Given the near-universal

health insurance coverage in Massachusetts [15], this analysis provided a unique opportunity to

characterize the antibiotic use-resistance relationship in a dataset that captures nearly all

antibiotic use in a population.

Methods

Antibiotic use data. Outpatient antibiotic use data was obtained from the Massachusetts All

Payer Claims Database [16], which covers >94% of outpatient prescriptions claims for

Massachusetts residents under the age of 65 [17]. Rates of use for each antibiotic class were

measured as the average daily number of antibiotic claims per 10,000 people during each

calendar month from January 2011 to May 2015. This data was subset to include only

individuals residing in 'Boston City' census tracks, as defined by the US Census Bureau [18], to

capture the antibiotic use patterns in the communities served by the hospitals in our resistance

dataset. We aggregated antibiotic use data by class according to the World Health

Organization's Anatomical Therapeutic Chemical Classification System [19] (**Supplementary**

Table 1). We included 5 antibiotic classes in our analysis, which together make up 74% of the

total outpatient antibiotic claims in Boston: penicillins, macrolides, quinolones, tetracyclines, and

nitrofurans. Given that bystander selection likely accounts for most of the antibiotic selection

experienced by *S. aureus*, *E. coli*, and *K. pneumoniae* [3], we included use data for all

antibiotics within each class, regardless of the target pathogen for which they were prescribed.

Antibiotic resistance data. Clinical microbiology data was obtained for *S. aureus*, *E. coli*, and

K. pneumoniae isolates collected at two tertiary care hospitals in Boston, MA: Brigham and

Women's Hospital (BWH) and Massachusetts General Hospital (MGH), from 2007-2019 and

2007-2016, respectively. Included in this analysis were all non-surveillance isolates from

inpatients and outpatients of all demographics, collected from the 5 most commonly infected

body sites across the 3 species: blood, skin and soft tissue, abscess/fluid, respiratory tract, and

urinary tract (**Supplementary Table 2**). Isolates of the same species that were collected from

the same patient within 2 weeks were assumed to represent a single infection and thus treated

as a single isolate. Our final dataset comprised of 47,219 *S. aureus*, 131,856 *E. coli*, and 27,245

K. pneumoniae isolates.

Antibiotic susceptibility testing was performed on each isolate either by automated broth

microdilution (Vitek 2, Biomerieux, Marcy l'Etoile, France) or by gradient diffusion. Resulting

minimum inhibitory concentration (MIC) values were $\log_2$-transformed. Due to variations in

hospital testing guidelines across the years, we excluded tests on isolates that did not report an

MIC value, either because a different test method was used (e.g., disk diameter) or due to

missing data. We excluded years/months from our analysis for each species-antibiotic

combination in each hospital where MIC values were reported for fewer than 80% of isolates or

only a subset of isolate types (e.g., only testing nitrofurantoin resistance in urinary tract

isolates). **Supplementary Table 3** lists date ranges for each species-antibiotic combination

included in our analysis. This study was approved by the Mass General Brigham Institutional

Review Board (Protocol number: 2016P001671).

Statistical methods. We quantified the extent of seasonality in antibiotic use and resistance by

fitting the use and MIC data to a pair of mathematical models, based on a previously described

method [9,10]. Both of our use and resistance models consist of (a) a sinusoidal component to

describe seasonal deviations from average year-round use and MICs and (b) a linear

component to adjust for secular trends, such as declines in use and resistance across years

[17,20]. The resistance model also includes covariates for age (in years) and sex to adjust for

variations in the underlying patient population across seasons. This model makes no

assumptions about the underlying mechanism of resistance and is generalizable to any species

and antibiotic [9,10]. We determined that there was seasonality in use or resistance if the 95%

confidence interval (CI) of the amplitude estimate did not include 0. We accounted for multiple

comparisons by applying the Benjamini-Hochberg correction with a 5% false discovery rate

(FDR) to the p-values of the amplitude estimates. See **Supplementary Material** for a complete

description of the methods.

We quantified the association between the observed seasonal patterns of use and resistance

using Spearman's rank correlations. To eliminate the impact of annual trends, we calculated

correlations between the average monthly seasonal deviates in use and resistance, aggregated

across years, rather than the raw use and MIC data. We define a 'seasonal deviate' as the

deviation in use or MIC at a given time of year from the year-round average, which we

estimated by the linear component of the models (see **Supplementary Material**).

Since the working model for the use-resistance relationship predicts that seasonal fluctuations

in resistance can lag use by up to 3 months [10], we calculated Spearman correlations between

use and resistance seasonal deviates with no lag and lags of 1, 2, and 3 months. In addition,

because we observed some seasonal patterns of resistance that better aligned with use of non-

cognate antibiotic classes, we calculated use-resistance correlations between each pairwise

combination of target antibiotics and use classes. We only included use-resistance pairs in this

analysis for which both use and resistance met our criterion for seasonality.

All analyses were performed in R version 3.6.2 [21]. Code is available at:

https://github.com/gradlab/use-resistance-seasonality

Results

Seasonality in antibiotic use varies across classes

The five antibiotic classes included in this study each displayed statistically significant seasonal

patterns of use (**Figure 1A**). Penicillins and macrolides were most frequently prescribed, with

year-round averages of 4.8 and 4.1 daily claims per 10,000 people, respectively. Quinolones,

tetracyclines, and nitrofurans were prescribed with year-round averages of 1.8, 1.0, and 0.5

daily claims per 10,000 people, respectively.

Penicillins had the greatest magnitude change in prescribing rate across seasons, with the

seasonal component having an amplitude of 1.10 additional daily claims per 10,000 people

(peak to mean) (95% CI, 0.96-1.30). This was followed by macrolides (amplitude, 0.74; 95% CI,

0.59-0.89), quinolones (amplitude, 0.081; 95% CI, 0.04-0.12), nitrofurans (amplitude, 0.04 95%

CI, 0.02-0.06), and tetracyclines use (amplitude, 0.03; 95% CI, 0.01-0.05) (**Figure 1B**).

The timing of peak prescribing varied by antibiotic class (**Figure 1B**). Macrolide and penicillin

use peaked in the winter, around late January (phase, 1.7 months; 95% CI, 1.3-2.1; note that

phase is indexed to 1.0 representing January 1st) and early February (phase, 2.2 months; 95%

CI, 2.0-2.5), respectively. Tetracycline and nitrofuran use peaked in the summer, around mid-

June (phase, 6.5 months; 95% CI, 4.6-8.5) and late August (phase, 8.8 months; 95% CI, 8.2-

9.4), respectively. Finally, quinolone use peaked twice a year in early January and early July

(phases, 1.0 (95% CI, 0.6-1.5) and 7.0 (95% CI, 6.6-7.5) months).

Seasonality in antibiotic resistance is prevalent across species and antibiotic classes

Resistance was seasonal for 10 out of 15 species-antibiotic combinations after adjusting for

patient age and sex (**Figure 2, Supplementary Figures 1-2**), with statistically significant

amplitudes of seasonality (FDR < 0.05) ranging from a peak $\log_2$(MIC) increase of 0.013 to

0.049 above the yearly average (**Figure 3**). Ciprofloxacin resistance and nitrofurantoin

resistance were seasonal in all three species with a 12-month period (**Figure 2,**

Supplementary Figures 1-2). Resistance to erythromycin in *S. aureus* was also seasonal with

a 12-month period (amplitude, 0.044; 95% CI, 0.009-0.079). Conversely, tetracycline resistance

was not seasonal in any of the three species (**Figure 2, Supplementary Figures 1-2**). The

seasonal patterns of resistance to penicillin class antibiotics were variable across species.

Oxacillin resistance in *S. aureus* was seasonal with a 12-month period (amplitude, 0.028; 95%

CI, 0.007-0.050), while both penicillin resistance in *S. aureus* (amplitude, 0.013; 95% CI, -0.007

-0.033) and amoxicillin/clavulanate resistance in *K. pneumoniae* (amplitude, 0.031; 95% CI, -

0.001-0.064) did not show evidence of seasonality. Ampicillin and amoxicillin/clavulanate

resistance in *E. coli* were the only species-antibiotic combinations that showed a 6-month period

in seasonality, with amplitudes of 0.032 (95% CI, 0.018-0.047) and 0.013 (95% CI, 0.002-

0.023), respectively. Despite having a slightly worse fit, the 12-month period model of ampicillin

resistance in *E. coli* also indicated seasonality (amplitude, 0.038; 95% CI, 0.017-0.060)

(**Supplementary Figure 3**).

Resistance peaked in the winter-spring months in all 10 seasonal species-antibiotic

combinations, with peaks ranging from early December to mid-April (**Figure 4**). Comparing

across species, resistance in *E. coli* (median phase, 2.9; interquartile range (IQR), 0.8) tended

to peak slightly later in the year than resistance in *S. aureus* (median phase, 1.5; IQR, 0.6) and

K. pneumoniae (median phase, 1.2; IQR, 1.2). Peak resistance to macrolides and penicillins in

S. aureus and the first peak in resistance to penicillins in *E. coli* occurred around the same time

of year as peak use of macrolides and penicillins. However, resistance to penicillins in *E. coli*

also peaked a second time during the year in late August and October, though use did not.

Resistance to nitrofurans in all 3 species peaked between 3.2 to 5.7 months after peak

nitrofuran use. Finally, resistance to quinolones in all 3 species peaked once a year about 0.6 to

2.1 months after the first peak in quinolone use.

Since the antibiotic use dataset was restricted to people under 65 years of age, we repeated the

resistance analysis excluding isolates from patients 65 years old and over. All species-antibiotic

combinations except oxacillin and erythromycin resistance in *S. aureus* continued to meet our

criterion for seasonality (95% CI of amplitude did not include 0) (**Supplementary Table 4**). In

the remaining 8 species-antibiotic combinations with significant seasonal amplitudes, resistance

peaked at the same time of year as in the analyses with the full dataset.

Seasonal resistance is positively correlated with use of winter-peaking antibiotic classes

Spearman correlation coefficients between use-resistance antibiotic pairs varied widely across

antibiotics, species, and lag times, ranging from -0.85 to 0.93 (**Figure 5, Supplementary**

Figure 4). The number of statistically significant correlations between use-resistance pairs was

maximized when the lag was 0 months in *S. aureus* and *K. pneumoniae* and 1 month in *E. coli*.

Resistance across multiple antibiotics was most positively correlated with use of winter-peaking

classes, penicillins and macrolides (median Spearman's ρ across all lags, 0.35; IQR, 0.64).

Resistance to most antibiotics also showed a negative correlation with use of summer-peaking

classes, tetracyclines and nitrofurans (median Spearman's ρ across all lags, -0.24; IQR, 0.45).

Finally, resistance was not significantly correlated with use of quinolones, which peaked twice a

year, for almost all antibiotics and species (median Spearman's ρ across all lags, -0.19; IQR,

0.30).

Discussion

Under a model in which antibiotic use drives resistance, seasonal variation in antibiotic

consumption is expected to be associated with variation in population-level resistance that is in

phase with or lagged up to a quarter period behind use [10]. However, we found that resistance

to all antibiotics, including those with summer and biannual peaks in use, best correlated

temporally with use of antibiotics with winter-peaking use—penicillins and macrolides—at a 0-to-

1-month lag.

The observed patterns of use and resistance for penicillins and macrolides were mostly

consistent with previous findings [6,7,9] and with model predictions [10]. Use of penicillins and

macrolides peaked in the winter, likely due to increased wintertime prescribing for respiratory

infections [12]. In *S. aureus*, resistance to oxacillin and erythromycin peaked in the winter and

was most correlated with penicillins and macrolides use with no lag. This was consistent with a

previous seasonality study that compared macrolide use and resistance in methicillin-resistant

S. aureus (MRSA) [7] and findings in other species-antibiotic combinations that have shown

winter peaks in use and resistance with little to no lag [6–8]. In *E. coli*, the first peaks in

ampicillin and amoxicillin/clavulanate resistance occurred in the winter and spring, lagging

penicillins use by about 0.5 to 2.5 months, respectively. Resistance to penicillins in *E. coli* also

showed a second peak in resistance 6 months later, in the absence of a second peak in use.

However, we note that a 12-month period model for ampicillin resistance in *E. coli* also met our

criterion for seasonality and showed a single winter peak in resistance, which is more consistent

with previous findings in *E. coli* [7,8].

Antibiotic classes with different seasonal patterns of use, such as nitrofurans and quinolones,

showed seasonal patterns of resistance inconsistent with model predictions and not readily

explained based on their patterns of use. Nitrofurans, which are almost exclusively used to treat

urinary tract infections (UTIs) [22], showed summer peaks in use during the same season as

peak UTI incidence [23–26]. However, resistance to nitrofurantoin in all 3 species peaked in the

winter/spring and lagged use by about 3 to 5.5 months. This was consistent with a previous

finding that nitrofurantoin resistance lagged use by 3-6 months in *E. coli* and *K. pneumoniae*

urinary tract isolates [11]. Quinolones, which are used to treat both respiratory infections and

UTIs [27], showed both winter and summer peaks in use, but only a single winter/spring peak in

ciprofloxacin resistance in all 3 species.

Several species-antibiotic combinations did not show seasonality in resistance. In each case,

this may be due to a lack of association between use and resistance, a lack of strong seasonal

variation in use of some antibiotic classes, or other factors, such as a signal too small to be

identified or dampened by the combination of inpatient and outpatient samples in our dataset.

The lack of seasonality in *S. aureus* resistance to penicillin may be explained by the high

prevalence of penicillin resistance in *S. aureus* [20] (83% in this dataset, **Supplementary Table**

3), which may limit the observable effect of increased wintertime use of penicillins. For *K.*

pneumoniae resistance to amoxicillin-clavulanate, the estimated amplitude of seasonality

missed the FDR cutoff for statistical significance, but additional data may narrow the confidence

intervals around the estimated amplitude. The absence of observed seasonality in tetracycline

resistance in all 3 species is consistent with a previous study that found no significant

correlation between tetracycline use and resistance in *E. coli* [7] and may be explained by the

lack of strong seasonal variation in tetracycline use (**Figure 1**).

Our finding that resistance to all antibiotics most correlated with use of winter-peaking antibiotic

classes suggests that the simple model in which use of a given antibiotic independently selects

for resistance is insufficient to explain the full seasonal use-resistance landscape. At least two

additional factors may contribute to this result. First, resistance to one antibiotic could be

indirectly selected for by increased wintertime use of a second antibiotic in bacteria that are co-

resistant to both antibiotics. Co-resistance between penicillins/macrolides and other antibiotics

is common across many bacterial species, including those in our study [28]. Therefore, the

winter peaks in resistance to other antibiotics may be driven by co-selection by winter-peaking

use of penicillins and macrolides. We might expect that selection by use of pencillins and

macrolides dominates over selection by other antibiotics because they are prescribed at

substantially higher rates and show greater seasonal variations in use [12]. Antibiotics with

higher rates of use showed stronger correlations between seasonal use and resistance [7]. In

addition, use of macrolides and penicillins have been shown to be more strongly correlated with

resistance than less frequently prescribed antibiotics [29].

Second, the observed winter peaks in resistance may be explained by increased wintertime

sampling of demographics and types of infections with higher overall rates of resistance, rather

than selection by antibiotic use. Rates of resistance have been shown to vary by age, sex, and

site of infection [30–32]; and, the incidence of infections from each of these groups can also

vary by season [26,33]. As such, an increased incidence of infections from groups with higher

rates of resistance could in turn lead to a winter spike in resistance, irrespective of patterns of

use.

There were several limitations to this study. First, factors other than antibiotic use could

contribute to seasonal variations in resistance, such as a sampling bias for populations with

higher levels of resistance during certain seasons. While we adjust for patient age and sex in

our model, we were unable to adjust for other characteristics, such as co-morbidities,

socioeconomic status, and access to healthcare. Second, although our study analyzed data

from a single city, some disparities still exist between the cohorts represented in the antibiotic

use and resistance datasets. We compared outpatient antibiotic use data from 97% of Boston,

MA residents under age 65 to antibiotic resistance data from both inpatients and outpatients at

two major Boston-area hospitals, with patient populations that skew towards older ages.

Previous studies have shown that community antibiotic use has strong impact on resistance in

both the hospital and community settings [34,35]. Additionally, our analyses excluding patients

over 65 showed that resistance patterns largely remained the same. The loss of seasonality in

oxacillin and erythromycin resistance in *S. aureus* suggests that these seasonal trends in

resistance are disproportionately driven by older populations. Third, due to data limitations, the

antibiotic use and resistance datasets for each species and antibiotic often spanned overlapping

but different year ranges. Therefore, we aggregated monthly use and resistance data across

years to perform our correlation analyses, adjusting for annual trends in use and resistance.

In conclusion, this work contributes to describing the complexity of the antibiotic use-resistance

relationship. Our finding that resistance to all antibiotics peaked in the winter/spring, regardless

of patterns of use, were consistent with previous studies from a range of geographic scales and

regions, including South Carolina [8], the USA overall [7,9], Israel [6], and the Netherlands [11].

This suggests a general phenomenon in which selection by those antibiotics with high-volume,

winter-peaking use and/or other ecological factors results in wintertime peaks of resistance for

all antibiotics, and indicates that the simplest model of antibiotic use independently driving

resistance to the same antibiotic is inadequate. Further work is needed to identify the factors

that shape the use-resistance landscape, with important implications for informing and

monitoring the outcome of efforts to reduce antibiotic resistance.

Acknowledgements

The authors thank R. Monina Klevens for assistance in acquiring the antibiotic prescribing data

and Enterprise Research Infrastructure & Services at Partners HealthCare for their

computational resources and support. This work was supported by funds from the HSPH Dean's

Award (to Y.H.G.) and Wellcome Trust (to Y.H.G.). D.S.S. is supported by the National Institutes

of Health training grant [T32AI132120].

Conflicts of interest

Y. H. G. and M. L. have received grant support from Pfizer. The other authors declare no

conflicts of interest.

References

1. U.S. Centers for Disease Control and Prevention. Antibiotic resistance threats in the
    United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-
    threats-report-508.pdf. Accessed 18 Sep 2020.

2. Jit M, Ng DHL, Luangasanatip N, et al. Quantifying the economic cost of antibiotic
    resistance and the impact of related interventions: Rapid methodological review,
    conceptual framework and recommendations for future studies. *BMC Med* 2020; 18:38.

3. Tedijanto C, Olesen SW, Grad YH, Lipsitch M. Estimating the proportion of bystander
    selection for antibiotic resistance among potentially pathogenic bacterial flora. *Proc Natl
    Acad Sci U S A* 2018; 115:E11988–95.

4. Hennessy TW, Petersen KM, Bruden D, et al. Changes in antibiotic-prescribing practices
    and carriage of penicillin-resistant *Streptococcus pneumoniae*: A controlled intervention
    trial in rural Alaska. *Clin Infect Dis* 2002; 34:1543–50.

5. Enne VI, Livermore DM, Stephens P, Hall LM. Persistence of sulphonamide resistance
    in *Escherichia coli* in the UK despite national prescribing restriction. *Lancet* 2001;
    357:1325–28.

6. Dagan R, Barkai G, Givon-Lavi N, et al. Seasonality of Antibiotic-Resistant
    Streptococcus pneumoniae That Causes Acute Otitis Media: A Clue for an Antibiotic-
    Restriction Policy? *J Infect Dis* 2008; 197:1094–102.

7. Sun L, Klein EY, Laxminarayan R. Seasonality and Temporal Correlation between
    Community Antibiotic Use and Resistance in the United States. *Clin Infect Dis* 2012;
    55:687–94.

8. Ramsey EG, Royer J, Bookstaver PB, et al. Seasonal variation in antimicrobial
    resistance rates of community-acquired *Escherichia coli* bloodstream isolates. *Int J
    Antimicrob Agents. Elsevier* 2019; 54:1–7.

9. Olesen SW, Torrone EA, Papp JR, Kirkcaldy RD, Lipsitch M, Grad YH. Azithromycin

Susceptibility Among *Neisseria gonorrhoeae* Isolates and Seasonal Macrolide Use. *J*

Infect Dis 2019; 219:619–23.

10. Blanquart F, Lehtinen S, Fraser C. An evolutionary model to predict the frequency of

antibiotic resistance under seasonal antibiotic use, and an application to Streptococcus

pneumoniae. *Proc R Soc B Biol Sci* 2017; 284:20170679.

11. Martínez EP, van Rosmalen J, Bustillos R, Natsch S, Mouton JW, Verbon A. Trends,

seasonality and the association between outpatient antibiotic use and antimicrobial

resistance among urinary bacteria in the Netherlands. *J Antimicrob Chemother* 2020;

75:2314–25.

12. Suda KJ, Hicks LA, Roberts RM, Hunkler RJ, Taylor TH. Trends and Seasonal Variation

in Outpatient Antibiotic Prescription Rates in the United States, 2006 to 2010. *Antimicrob*

Agents Chemother 2014; 58:2763–6.

13. Kluytmans J, Van Belkum A, Verbrugh H. Nasal Carriage of I: Epidemiology, Underlying

Mechanisms, and Associated Risks. *Clin Microbiol Rev* 1997; 10:505–20.

14. Huttenhower C, Gevers D, Knight R, et al. Structure, function and diversity of the healthy

human microbiome. *Nature* 2012; 486:207–14.

15. Berchick ER, Barnett JC, Upton RD. *Current population reports, P60-267 (RV), Health*

Insurance Coverage in the United States: 2018. Washington, DC: US Government

Printing Office, 2019.

16. Center for Health Information and Analysis. *Massachusetts All Payer Claims Database*,

2019. https://www.chiamass.gov/ma-apcd/. Accessed 16 Sep 2020.

17. Klevens RM, Caten E, Olesen SW, DeMaria A, Troppy S, Grad YH. Outpatient Antibiotic

Prescribing in Massachusetts, 2011–2015. *Open Forum Infect Dis* 2019; 6:ofz159.

18. US Census Bureau. American fact finder, 2020. https://data.census.gov/cedsci/.

Accessed 16 Sep 2020.

19. World Health Organization Collaborating Centre for Drug Statistics Methodology.

Structure and Principles, 2020. https://www.whocc.no/atc/structure_and_principles/.

Accessed 13 Jun 2020.

20. Kanjilal S, Sater MRA, Thayer M, et al. Trends in Antibiotic Susceptibility in

Staphylococcus Aureus in Boston, Massachusetts, from 2000 to 2014. *J Clin Microbiol*

2018; 56:e01160-17.

21. R Core Team. R: A language and environment for statistical computing. R Foundation

for Statistical Computing, Vienna, Austria.

22. Guay DR. An Update on the Role of Nitrofurans in the Management of Urinary Tract

Infections. *Drugs* 2001; 61:353–64.

23. Stamm WE, McKevitt M, Roberts PL, White NJ. Natural History of Recurrent Urinary

Tract Infections in Women. *Rev Infect Dis* 1991; 13:77–84.

24. Anderson JE. Seasonality of symptomatic bacterial urinary infections in women. *J

Epidemiol Community Health* 983; 37:286–90.

25. Czaja CA, Scholes D, Hooton TM, Stamm WE. Population-Based Epidemiologic

Analysis of Acute Pyelonephritis. *Clin Infect* 2007; 45:273–80.

26. Rosello A, Pouwels KB, Domenech De Cellès M, et al. Seasonality of urinary tract

infections in the United Kingdom in different age groups: Longitudinal analysis of The

Health Improvement Network (THIN). *Epidemiol Infect* 2018; 146:37–45.

27. Hooper DC. Clinical applications of quinolones. *Biochim Biophys Acta* 1998; 1400:45-61.

28. Chang H-H, Cohen T, Grad YH, Hanage WP, O'Brien TF, Lipsitch M. Origin and

Proliferation of Multiple-Drug Resistance in Bacterial Pathogens. *Microbiol Mol Biol Rev*

2015; 79:101–16.

29. Olesen SW, Barnett ML, Macfadden DR, et al. The distribution of antibiotic use and its

association with antibiotic resistance. *Elife* 2018; 7:e39435.

30. Mcgregor JC, Elman MR, Bearden DT, Smith DH. Sex- and age-specific trends in

antibiotic resistance patterns of *Escherichia coli* urinary isolates from outpatients. *BMC*

Fam Pract 2013; 14:25.

31. Garcia A, Delorme T, Nasr P. Patient age as a factor of antibiotic resistance in

methicillin-resistant *Staphylococcus aureus. J Med Microbiol* 2017; 66:1782–9.

32. Lagacé-Wiens PRS, DeCorby MR, Baudry PJ, Hoban DJ, Karlowsky JA, Zhanel GG.

Differences in antimicrobial susceptibility in *Escherichia coli* from Canadian intensive

care units based on regional and demographic variables. *Can J Infect Dis Med Microbiol*

2008; 19:282–6.

33. Leekha S, Diekema DJ, Perencevich EN. Seasonality of staphylococcal infections. *Clin*

Microbiol Infec. 2012; 18:927–33.

34. Knight GM, Costelloe C, Deeny SR, et al. Quantifying where human acquisition of

antibiotic resistance occurs: A mathematical modelling study. *BMC Med* 2018; 16:137.

35. Macfadden DR, Fisman DN, Hanage WP, Lipsitch M. The Relative Impact of Community

and Hospital Antibiotic Use on the Selection of Extended-spectrum Beta-lactamase-

producing *Escherichia coli. Clin Infect Dis* 2019; 69:182–188.

Figures

Figure 1. **Seasonal patterns of antibiotic use by class. (A)** Average daily antibiotic claims

per 10,000 people by calendar month in Boston, MA from 2011 to 2016. Lines indicate LOESS

smoothing curves and shaded regions indicate 95% confidence intervals. **(B)** Sinusoidal model

fits for monthly prescribing rate. Points indicate monthly mean seasonal deviates in average

daily antibiotic claims per 10,000 people by calendar month and error bars indicate the standard

error of the mean. Lines indicate the point estimate for the amplitude and phase of the

sinusoidal model. Shaded regions indicate the 95% confidence intervals for the amplitude.

Asterisks indicate the amplitude of seasonality is statistically significant (FDR < 0.05).

Figure 2. Seasonality of antibiotic use and resistance by class in *Staphylococcus aureus*.

Solid lines indicate point estimates of the amplitude and phase from the best-fitting sinusoidal

models of resistance to each antibiotic, colored by class. Dashed grey lines indicate point

estimates of the amplitude and phase of sinusoidal models for use of the corresponding

antibiotic class. Shaded regions indicate the 95% confidence intervals for the amplitude. Points

indicate the monthly mean seasonal deviates in resistance adjusted for age and sex, and error

bars indicate the standard error of the mean. Asterisks indicate the amplitude of seasonality in

resistance is statistically significant (FDR < 0.05).

Figure 3. Amplitudes of seasonality of resistance by species and antibiotic class.
Comparison of amplitudes estimated from best-fitting sinusoidal models of resistance across antibiotics in *Staphylococcus aureus*, *Escherichia coli*, and *Klebsiella pneumoniae*. Error bars indicate 95% confidence intervals of the amplitude. Point color indicates the antibiotic class. AMC, Amoxicillin-Clavulanate; AMP, Ampicillin; CIP, Ciprofloxacin; ERY, Erythromycin; NIT, Nitrofurantoin; OXA, Oxacillin; PEN, Penicillin; TET, Tetracycline.

Figure 4. Phases of seasonality of use and resistance by species and antibiotic class.

Points indicate peak month(s) of seasonal resistance estimated by the best-fitting sinusoidal

model for each species-antibiotic combination, and error bars indicate the 95% confidence

intervals. Vertical lines indicate the peak month(s) of seasonal use estimated by the best-fitting

sinusoidal model for each antibiotic class, and the shaded regions indicate the 95% confidence

intervals. Included are species-antibiotic combinations for which the amplitude met our criteria

for seasonality (95% confidence intervals did not cross 0). AMC, Amoxicillin-Clavulanate; AMP,

Ampicillin; CIP, Ciprofloxacin; ERY, Erythromycin; NIT, Nitrofurantoin; OXA, Oxacillin.

Figure 5. Spearman correlations between seasonal use and resistance with 0-3 months

lag in *S. aureus*. Spearman's rank correlation coefficients were calculated between the monthly

mean age- and sex-adjusted seasonal deviate in resistance (in $\log_2(MIC)$) and the monthly

mean seasonal deviate in use (in average daily claims per 10,000 people) with 0, 1, 2, or 3

months lag between use and resistance, for every pairwise combination of antibiotics and

classes. Error bars indicate the 95% confidence intervals. Colors indicate the use antibiotic

class. Mac, Macrolides; Nit, Nitrofurantoin; Pen, Penicillins; Qui, Quinolones; Tet, Tetracyclines.

CIP, Ciprofloxacin; ERY, Erythromycin; NIT, Nitrofurantoin; OXA, Oxacillin.